Add to Watchlist Create Alerts

Real-Time Last Update

Volume

Stocks in play: Bausch + Lomb Corporation

Baystreet.ca - Baystreet - Tue Sep 12, 2023

Announced the U.S. commercial launch of MIEBO (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved for DED that directly targets tear evaporation. Bausch + Lomb Corporation shares T.BLCO are trading unchanged at $23.87.

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

Premarket: U.S. futures fall as chip stocks drag, Fed rate decision awaited

The close: Major indexes fall after wage data; cannabis shares surge on U.S. regulatory move

The close: Stocks higher as investors focus on Fed moves

The close: Major North American indexes rise as megacap tech stocks rally

Why this money manager is venturing back into emerging markets and adding more U.S. tech

How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy

report on business

Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders

The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market